Gilead Sciences Inc. closed $3.98 short of its 52-week high ($87.87), which the company achieved on January 19th.

Shares of Gilead Sciences Inc. GILD dropped 0.13% to $83.05 Tuesday, on what proved to be an all-around mixed trading session ...

Today, Benzinga's options scanner spotted 9 options trades for Gilead Sciences. This is not a typical pattern. The sentiment ...

In the latest supply deal on the active pharmaceutical ingredients (API) front, Gilead Sciences has tapped South Korea’s ...

Gilead Sciences’ Kite Pharma will sell its stake in China’s Fosun Kite Biotechnology nearly eight years after forming the ...

There are now multiple forms of injectable PrEP medications. Lenacapavir, which is Gilead's injectable drug, differs from ...

Gilead Science’s Kite Pharma is separating from its cell therapy joint venture with Fosun Pharma in China, handing Fosun the ...

Defendant Yisel Lopez has been found in contempt for violating an asset freeze order through the sale of property.

Gilead Sciences (GILD) stock price has staged a strong comeback this year, helped by strong earnings and a recent $40 million ...

Gilead Sciences’ capsid inhibitor lenacapavir has the most competitive potential in long-acting combination regimens in HIV, ...

Lenacapavir, a very expensive drug, is not available in India and many other countries. If the Indian Patent Office clears ...

The latest trading day saw Gilead Sciences (GILD) settling at $83.08, representing a -0.1% change from its previous close.